AVEO lands $25M milestone; MedImmune posts 184 job openings;

 @FierceBiotech: Blockbuster antibodies now face quick onslaught of biosimilars. Article | Follow @FierceBiotech

 @JohnCFierce: In a PwC survey, the FDA gets a better grade for guidance but gets an 'F' on the review process. Story | Follow @JohnCFierce

> AVEO Pharmaceuticals is in line for $25 million in milestones now that OSI has decided to exercise its option on elements of the biotech company's development platform. OSI will pay AVEO $25 million in license expansion fees; $12.5 million was paid upon delivery of the notice of option exercise and $12.5 million will be paid following the successful transfer of the applicable technology from AVEO to OSI. The transfer is expected to be completed in July 2011. Release

> MedImmune has posted 184 job openings on its web site. The biotech is filling positions in Gaithersburg and Frederick. Story

> Collegium Pharmaceutical has completed the spin-out of Onset Therapeutics, its wholly owned subsidiary focused on the dermatology market. Release

> Tolerx and the Cancer Research Institute have forged a collaboration to accelerate development of TRX518, an anti-GITR antibody for cancer. Release

> For years now biopharma companies have been developing antidepressants that can boost levels of serotonin and noradrenaline. Now a Swedish investigator at Lund University says that inflammation--which can deplete serotonin-may be a root cause of depression and a new signpost for clinicians to observe. Report

> Using magnetic resonance imaging technology, a group of researchers has identified three distinct "neural signatures"--markers that can potentially be used to identify autism at an early stage. News

> Quintiles has inked a non-exclusive deal with London Genetics Limited to offer the pharmaceutical industry pharmacogenetics solutions to advance personalized medicine. Financial terms of the deal were not disclosed. Report

> A new marker for Alzheimer's could point the way to a more effective method to treat the memory-wasting illness. Report

And Finally... UK scientists say that long index fingers are a sign of lower risk for prostate cancer. "Relative finger length could be used as a simple test for prostate cancer risk," said Ros Eeles, one of the study's lead authors. Story

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.